OBIO Stock Analysis: Buy, Sell, or Hold?
OBIO - Orchestra BioMed Holdings, Inc. Ordinary Shares
$3.93
-0.18 (-4.38%)
▼
5d:
-1.5%
30d:
-7.96%
90d:
+5.93%
BUY
MODERATE Confidence
Analysis Updated: May 7, 2026 12:00 AM ET
Earnings: May 11, 2026
2d
Smart Money Distribution
OBIO is up 8.2% this week, but smart money is buying puts. Top strike: $2.5 2026-06-18 with 1 OI. Put ratio: 100% View Scanner →
Strength: 9.1/10
Get Alerted When OBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: OBIO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: OBIO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: OBIO is currently trading at $3.93, which is considered oversold relative to its 30-day fair value range of $4.00 to $4.39.
Technical Outlook: Technically, OBIO is showing sideways momentum. Immediate support is located at $3.77, while resistance sits at $4.24. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: OBIO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.43 (+216.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OBIO is showing sideways momentum. Immediate support is located at $3.77, while resistance sits at $4.24. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: OBIO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.43 (+216.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.00 -
$4.39
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
62.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.4%)
- BULLISH: Trading 216.2% below Wall St target ($12.43)
Trading Range Analysis
30-Day Trading Range
$4.00 -
$4.39
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.67
(17.0%)
Support & Resistance Levels
Support Level
$3.78
Resistance Level
$4.24
Current Trend
Sideways
Technical data as of
May 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.31
Wall Street Target
$12.43
(+216.2%)
Revenue Growth (YoY)
12120.2%
Profit Margin
-157.4%
Share & Embed Analysis
Last updated: May 08, 2026 8:21 AM ET
Data refreshes hourly during market hours. Next update: 9:21 AM
Data refreshes hourly during market hours. Next update: 9:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OBIO showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David P Hochman
BUY
10000 shares
2026-03-13
David P Hochman
BUY
5000 shares
2025-11-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$27 | 55 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$131 | 48 HOLD |
|
EXEL
Exelixis Inc |
BUY
20 analysts |
$48 | 67 BUY |
